Furthermore, we also investigated the therapeutic value of the six‐gene signature and found that it could help predict the response to immune checkpoint inhibitors (ICIs) and that three genes (GLTP, ISG20 and UPP1) in the six‐gene signature might serve as potential drug targets for cervical cancer. This evidence concerns the gene ISG20 and cervical carcinoma.